Examkin

Question

Difficulty: MediumDiagnostic and Screening Test Performance

An obstetrician is counseling a 28-year-old nulliparous woman at 10 weeks gestation regarding noninvasive prenatal testing (NIPT) utilizing cell-free DNA. The clinic has recently updated its screening protocol. Previously, NIPT was offered exclusively to pregnant women aged 35 and older, a demographic known to have a higher baseline incidence of fetal aneuploidy. Under the newly implemented protocol, the exact same NIPT assay is offered universally to all pregnant women, significantly lowering the overall prevalence of aneuploidy in the clinic's total screened population. Assuming the intrinsic properties of the cell-free DNA assay remain identical, which of the following best describes the expected changes in the positive predictive value (PPV) and negative predictive value (NPV) of this diagnostic test when applied to the universal screening group compared to the advanced maternal age group?

  1. The positive predictive value will decrease, and the negative predictive value will increase.Answer
  2. B
    The positive predictive value will increase, and the negative predictive value will decrease.
  3. C
    The positive predictive value will decrease, and the negative predictive value will remain unchanged.
  4. D
    The positive predictive value will remain unchanged, and the negative predictive value will increase.
  5. E
    Both the positive predictive value and the negative predictive value will remain unchanged.

Answer

The positive predictive value will decrease, and the negative predictive value will increase.
The performance metrics of a diagnostic test include both intrinsic properties (sensitivity and specificity) and population-dependent properties (predictive values). When the screening protocol expands to include all pregnant women regardless of age, the overall prevalence of fetal aneuploidy in the screened population drops significantly. The positive predictive value is the probability that a person with a positive test result actually has the disease (PPV=TPTP+FPPPV = \frac{TP}{TP + FP}). As prevalence decreases, the number of true positive (TP) cases drops while false positive (FP) cases remain proportionally stable, resulting in a decreased positive predictive value. Conversely, the negative predictive value is the probability that a person with a negative result truly does not have the disease (NPV=TNTN+FNNPV = \frac{TN}{TN + FN}). Because a lower prevalence yields a massive increase in true negatives (TN) relative to false negatives (FN), the negative predictive value increases.

Step-by-Step Solution

1
Identify the underlying change in the clinical scenario.
The test is moving from an older patient population (high prevalence of aneuploidy) to a universal patient population that includes younger women (lower overall prevalence of aneuploidy).
Recognizing the shift in disease prevalence is the prerequisite for calculating the impact on test performance metrics.
2
Determine the effect of decreased disease prevalence on positive predictive value.
As prevalence decreases, the ratio of true positives to false positives decreases, meaning the PPV must drop.
PPV is mathematically defined as PPV=TPTP+FPPPV = \frac{TP}{TP + FP}. A lower prevalence means fewer true positives in the population, making any positive result more likely to be a false positive.
3
Determine the effect of decreased disease prevalence on negative predictive value.
As prevalence decreases, the ratio of true negatives to false negatives increases, meaning the NPV must rise.
NPV is defined as NPV=TNTN+FNNPV = \frac{TN}{TN + FN}. A lower prevalence means a vast majority of the population is genuinely disease-free, making any negative result highly reliable.

Key Concept

Predictive values (PPV and NPV) depend directly on the prevalence of the disease in the tested population, whereas sensitivity and specificity do not.
Rate this question

Topics

Diagnostic and Screening Test Performance

More questions from this topic